CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

It’s a synthetic version of the hormone GLP-1, which helps regulate our metabolism ... Some of these newer iterations, the dual agonists, have such significant weight loss that not everybody ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

The weekly injections and gastrointestinal side effects ... a subcutaneously injected, long-acting GLP-1 agonist drug. A Phase 1/2 test is underway in the U.S., enrolling participants who are ...

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

I'm broadly encouraged, although I wanted to hear more about the three GLP-1 agonist assets ... advantage (as it reduces the number of injections per annum patients require).

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Demand for weight loss injections has skyrocketed in just one year, with Google searches for the treatment rising by almost ...